Can serum Glutathione-S-transferase levels in carcinoma cervix be a predictor of radiation response?

Abstract

We conducted a pilot study wherein serum Glutathione-S-transferase levels were measured before and after radiotherapy in carcinoma cervix patients and correlated with response to treatment dudng a two-year follow-up period. Out of 17 patients who received radiotherapy, 9 showed a significant decrease (p< 0.005) while 8 showed significant increase (p< 0.004) in post radiotherapy glutathione-S-transferase values as compared to pre treatment values respectively. These patients were followed up for two years and we observed that 71% who had significant increase in post radiotherapy values had relapse of cancer within 2 years where as 66% of those who had significant decrease in post radiotherapy values had no evidence of relapse. This shows that alterations in serum Glutathione-Stransferase levels may help us to predict radiation response

The significance of reduced glutathione and glutathione S-transferase during chemoradiotherapy of locally advanced cervical cancer

“…Prabhu et al [26] measured levels of serum GST before and after radiation. The study results showed that alterations in serum GST levels may help to predict the response to radiation.…”

Study of Glutathione-s-transferase and Reduced Glutathione Receiving Chemotherapy

“…Our findings indicate that there were no statistically important improvements in GST concentrations during therapy. However, as patients were compared based on when their condition worsened following chemoradiation, a statistically important discrepancy was found [17][18][19][20].…”

Oxidative stress in cervical cancer pathogenesis and resistance to therapy

“…Prabhu et al suggested that alterations in GST serum levels might be used as a predictive tool to predict response to radiotherapy in patients with CC. 92 It was revealed that patients with CC who did not show any response after chemo/radiotherapy had significantly higher GSH levels compared with patients who responded. 93 Reduced amount of GSH might contribute to CC pathogenesis through the excessive generation of ROS.…”

“…Consequently, MAP17 or SGLT1 can be used as a useful prognostic marker for patients with CC undergoing chemo/radiotherapy. Prabhu et al suggested that alterations in GST serum levels might be used as a predictive tool to predict response to radiotherapy in patients with CC . It was revealed that patients with CC who did not show any response after chemo/radiotherapy had significantly higher GSH levels compared with patients who responded .…”